Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.31 |
| ▸ | GCK | P35557 | 2/20 | 0.31 |
| ▸ | GCKR | Q14397 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31416677 | 0.83 | ALDH1A1 (0.39) | ALDH1A1HSD17B10TDP1TRPV4 | |
| SCHEMBL31190599 | 0.78 | ALDH1A1 (0.40) | ALDH1A1HSD17B10TDP1TRPV4GCK | |
| SCHEMBL31416658 | 0.74 | TRPV4 (0.31) | TRPV4 | |
| SCHEMBL10694027 | 0.72 | ALDH1A1 (0.41) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL31713455 | 0.72 | LMNA (0.33) | ALDH1A1TDP1TRPV4GCKGCKR | |
| SCHEMBL25249974 | 0.72 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL31190709 | 0.71 | ALDH1A1 (0.44) | ALDH1A1HSD17B10TDP1TRPV4 | |
| SCHEMBL244098 | 0.69 | TRPV4 (0.52) | ALDH1A1HSD17B10TDP1TRPV4 | |
| SCHEMBL29948975 | 0.69 | TRPV4 (0.52) | ALDH1A1HSD17B10TDP1TRPV4 | |
| SCHEMBL16969 | 0.69 | ALDH1A1 (0.46) | ALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2024220747-A2 | FLUORINATED CYCLIC DERIVATIVES OF SULFONAMIDES AND SULFONES, AND COMPOSITIONS AND METHODS THEREOF | Lysoway Therapeutics, Inc. (US) | 2024-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | ALDH1A1 3204/4885HSD17B10 3178/4885TDP1 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.